May 8, 2025

Redwire Chief Scientist Dr. Kenneth Savin Named to TIME’s 2025 TIME100 Health List of the 100 Most Influential People in Global Health

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE:RDW), a leader in space infrastructure for the next generation space economy, announced today that Dr. Kenneth Savin, Redwire Chief Scientist, has been named to this year’s TIME100 Health, a list of the 100 most influential people in global health. The prestigious recognition honors individuals making groundbreaking contributions to the future of health and medicine.

Dr. Savin was selected for his deep expertise in the pharmaceutical industry and his pioneering work accelerating cutting-edge space biotech research capabilities, which leverage microgravity to improve human health on Earth. At Redwire, Dr. Savin has overseen trailblazing investigations onboard the International Space Station (ISS) in partnership with NASA and the ISS National Laboratory. Redwire successfully bioprinted the first human knee meniscus and first live human cardiac tissue using its BioFabrication Facility on the ISS. These breakthroughs address challenges faced by millions of people worldwide through the application of organ transplantation and tissue therapy and advance the next generation of pharmaceutical therapies.

Dr. Savin has coordinated groundbreaking protein crystallization investigations onboard the ISS with pharmaceutical companies like Eli Lilly and Company (Lilly) and Bristol Myers Squibb using Redwire’s in-space pharmaceutical lab, PIL-BOX, for improved drug development. These investigations have focused on various applications to address the world’s most prevalent conditions, including antiviral, antifungal, and antiseizure applications, heart disease, and bone loss.

“I am deeply honored to be recognized as one of the TIME100’s most influential figures in health for 2025,” said Dr. Savin. “Through microgravity research and development, we are seeing extraordinary scientific achievements that are accelerating game changing biomedical breakthroughs not possible on Earth and with enormous potential for the future of human health. I am honored and proud to be part of the Redwire team and excited to see what we are able to accomplish next."

Before joining Redwire, Dr. Savin had a successful 20-year career in the pharmaceutical industry working at Lilly, where he led various research and development teams, along with five investigations onboard the ISS. Following his time at Lilly, Dr. Savin was the Senior Director of In-Space Production Applications at the Center for the Advancement of Science In Space (manager of the ISS National Lab), where he worked with NASA to develop the In Space Production and Applications program to develop products in space that will benefit life on the Earth.

The full TIME100 Health list can be found here.

About Redwire

Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire's proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire's approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20250507519094/en/

Media Contact:
Tere Riley
Tere.Riley@redwirespace.com
+1 321-831-0134

OR

Investors:
investorrelations@redwirespace.com
+1 904-425-1431

Source: Redwire Corporation